Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

I0360000

Ipratropium bromide

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Ipratropium bromide monohydrate, Atropine isopropyl bromide

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C20H30BrNO3 · H2O
Número CAS:
66985-17-9
Peso molecular:
430.38
Número MDL:
MFCD00792907
Código UNSPSC:
41116107
ID de substância PubChem:
329815309
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

ipratropium

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

cadeia de caracteres SMILES

O.[Br-].CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c3ccccc3

InChI

1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19?,21?;;

chave InChI

KEWHKYJURDBRMN-XSAPEOHZSA-M

Informações sobre genes

human ... CHRM3(1131)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Ipratropium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0000276

Ipratropium impurity A, European Pharmacopoeia (EP) Reference Standard

I0361000

Ipratropium bromide impurity B, European Pharmacopoeia (EP) Reference Standard

1347507

Ipratropium bromide, United States Pharmacopeia (USP) Reference Standard

1347518

Ipratropium bromide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1347530

Ipratropium bromide Related Compound C, United States Pharmacopeia (USP) Reference Standard

1347529

Ipratropium bromide Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP625

Ipratropium bromide, British Pharmacopoeia (BP) Reference Standard

BP626

8s-Isopropyl-3β-hydroxytropanium bromide, British Pharmacopoeia (BP) Reference Standard

BP1232

Ipratropium bromide Impurity D, British Pharmacopoeia (BP) Reference Standard

PHR2873

Ipratropium Bromide Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3017

Ipratropium Bromide Related Compound A, pharmaceutical secondary standard, certified reference material

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302 + H332,H319

Classificações de perigo

Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Maciej Ciebiada et al.
Allergy and asthma proceedings, 35(5), 72-79 (2014-10-09)
Persistent airways obstruction (PAO) may affect some patients with severe asthma and may significantly worsen the prognosis. This study was designed to detect risk factors associated with persistent airflow limitation in nonsmoking adult patients with severe asthma. A total of
Sharath S Hegde et al.
The Journal of pharmacology and experimental therapeutics, 351(1), 190-199 (2014-08-08)
The objective of the present studies was to characterize the pharmacologic properties of GSK-961081 [TD-5959; (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl) piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate], a novel first-in-class inhaled bifunctional compound possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA). In competition radioligand binding studies
Moritz Beck-Broichsitter et al.
Journal of pharmaceutical sciences, 103(8), 2585-2589 (2014-07-06)
Nebulization of active pharmaceutical ingredient (API) solutions is a well-established means to achieve pulmonary drug deposition. The current study identified the impact of formulation variables on the aerosolization performance of the eFlow(®) rapid with special respect to optimized lung application.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica